Ipsen giv­en an ad­comm date for palo­varotene; Am­brx Bio­phar­ma looks to se­cure $75M in lat­est se­cu­ri­ties of­fer­ing

Ipsen has been giv­en an ad­vi­so­ry com­mit­tee date of June 28 for its re­sub­mit­ted NDA for palo­varotene as a po­ten­tial treat­ment for fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va (FOP).

In De­cem­ber of last year, the FDA re­ject­ed the drug, ask­ing for more da­ta from its ex­ist­ing stud­ies. But the agency is giv­ing the French phar­ma an­oth­er shot, set­ting a PDU­FA date for Aug. 16, 2023, as more in­for­ma­tion on palo­varotene’s clin­i­cal tri­al will be in­clud­ed in the re­sub­mis­sion. This com­pris­es more analy­ses across the clin­i­cal tri­al pro­gram, in­clud­ing the first Phase III study that was car­ried out in pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER